Alerta

Replimune Group Inc. (REPL)

NasdaqGS: REPL · Precio en tiempo real · USD

14.63

-0.34 (-2.27%)

Al cierre: Aug 18, 2026, 3:59 PM

14.42

-1.46%

Premercado: 6:27 AM

-2.27% (1D)

Precio de compra	n/a
Capitalización de mercado	1.38B
Ingresos (TTM)	n/a
Beneficio neto (TTM)	-297.01M
Beta	0.90
EPS (TTM)	-3.15
Ratio PER (TTM)	n/a
Adelante PE	-10.7
P/B (TTM)	11.63
P/S (TTM)	n/a
Earnings Date	Nov 5, 2026

Precio de venta	n/a
Volumen	3,679,874
Volumen medio (20D)	5,944,047
Abierto	14.65
Anterior Cerrar	14.97
Rango del día	14.05 - 14.69
Rango de 52 semanas	1.50 - 15.71
analista	Buy
Precio objetivo	19.5 (33.29%)
Dividendos	n/a
Fecha ex dividendo	n/a

Acerca de REPL

Replimune Group, Inc., a clinical-stage biotechnology company, focuses on the development and commercialization of oncolytic immunotherapies to treat cancer in the United States and the United Kingdom. The company's proprietary oncolytic immunotherapy product candidates are designed and intended to activate the immune system against cancer. Its lead product candidate is RP1, a selectively replicating version of HSV-1 that expresses GALV-GP R(-) a...

[Leer más]

Industria Biotechnology

Sector Healthcare

IPO Fecha Jul 20, 2018

Empleados 465

Bolsa de Valores NasdaqGS

Símbolo bursátil REPL

Sitio web https://www.replimune.com

Perfil completo de la empresa

Desempeño financiero

En 2026, los ingresos de Replimune fueron 0, un aumento de undefined% en comparación con 0 del año anterior. Las ganancias fueron -313.94M, un aumento de 26.95%.

Estados financieros

Pronóstico del analista

Según las calificaciones de los analistas de 6, la calificación promedio de las acciones de REPL es "Buy". El pronóstico del precio de las acciones a 12 meses es 19.5, que es Potencial alcista de 33.29% del último precio.

Previsiones bursátiles

Sorpresa de resultados

Replimune ha publicado sus resultados trimestrales en Aug 14, 2026:

Ingresos de $0 falla las estimaciones por $0, con NaN% Crecimiento interanual.

EPS de -0.72 supera las estimaciones en 0.05, con 24.21% Crecimiento interanual.

Próxima publicación de resultados

Está previsto que Replimune Group Inc. publique sus resultados el Nov 5, 2026, antes de que se abra el mercado.
Los analistas proyectan ingresos de ... Actualizar

Noticias

5 días hace · Simply Wall St.

Replimune Group (REPL) Wins FDA Approval For Advanced Melanoma Treatment

Replimune Group (NasdaqGS:REPL) received FDA accelerated approval for TUDRIQEV (RP1) in combination with nivolumab to treat advanced cutaneous melanoma after anti PD 1 therapy. This marks the first FD...

1 semana hace · Stocktwits

Why Did ABCL, REPL, ABNB Stocks Hit 52-Week Highs Today?

AbCellera, Replimune and Airbnb reached fresh highs as strong drug data, new funding and better-than-expected earnings boosted investor confidence.

1 semana hace · Stocktwits

REPL Stock Hits Near 18-Month High On Pricing Of $150M Offering – But, Retail Sees Share Price ‘Unwinding Over Time’

The firm priced about 9.7 million shares at $12.06 each, in line with Friday’s closing price.

1 semana hace · Barrons.com

This Biotech’s Drug Could Treat Hot Flashes. The Stock Is Up 34% on Good News.

New data show a single dose of AbCellera’s menopause treatment, ABCL635, reduces how often patients with menopause experience hot flashes.

1 semana hace · Stocktwits

Replimune’s First Commercial Drug Arrives—With A 2027 Cash Cliff And 2030 Finish Line

Replimune’s Tudriqev was granted accelerated approval by the FDA earlier this week, following two prior complete response letters and a 10-3 advisory committee vote in late July recommending the thera...

Página 1 de 2

Replimune Group Inc. (REPL)